PPD - Austin Research Unit
Austin, Texas, 78744, United States
NCT Number: NCT06189404
A phase 1, open-label, drug-drug interaction study to evaluate the effect of multiple doses of tigulixostat on the pharmacokinetics of single-dose theophylline in healthy adult volunteers.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Austin, Texas, 78744, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
300 mg oral dose
Other names: LC350189
400 mg oral dose
Time frame: Up to 72 hours
Time frame: Up to 72 hours
Time frame: Up to 72 hours
Time frame: Up to Day 28
Time frame: Up to 24 hours
Time frame: Up to 24 hours
LG Chem
Industry
A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Multiple Oral Doses of Tigulixostat on the Pharmacokinetics of a Single Oral Dose of Theophylline
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06056570
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Clearwater, Florida, United States
View Trial DetailsNCT06439602
Arthritis, Arthritis, Gouty
Foley, Alabama, United States
View Trial DetailsNCT03934099
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT05586958
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial Details